Ingersoll Rand heads into its July 30 earnings report with the stock recovering sharply from a tariff-driven stumble, while positioning signals remain relaxed rather than charged.
The stock has rallied 10% over the past month to $84.40, broadly in line with peers — ITW rose 2.5% on the week, GGG jumped 6.6%, and NDSN added 2.3%. Options traders show no sign of bracing for a big move. The put/call ratio is 0.23, essentially at its 20-day average of 0.228 and close to the lowest reading of the past year. That is a decisively call-heavy stance heading into a print that has historically moved the stock materially in both directions. The borrow market echoes that calm. Availability is extraordinarily loose at over 1,160% — meaning shares to borrow vastly outnumber shares already shorted — and the cost to borrow is a negligible 0.50%. Short interest itself, at 4.1% of the free float, has edged up around 2.7% on the week but remains well within a range it has held all year. Bears are not pressing their case.
The debate heading into this print centers squarely on margins and organic volume. The bear case is recent and concrete: IR cut its 2025 organic sales guidance after Q2 results, blaming lower tariff-related pricing, and the stock fell 11.4% on the day. Adjusted EBITDA margins deteriorated to 27.0%, a 40 basis point year-over-year decline, as acquisition drag and volume deleverage offset operational gains. Analyst targets have drifted lower in recent months — Morgan Stanley cut its target from $92 to $80 in June while keeping a neutral-equivalent rating, and Stifel trimmed to $84 last week, effectively valuing the stock at where it trades today. The consensus mean target of $93 implies modest upside, but two of the most recent actions have been cautious. Bulls counter with a real backlog story: a 16% increase in backlog and a book-to-bill of 1.07x point to demand that has not evaporated, and Citi and Barclays both retain positive ratings with targets well above the current price at $109 and $95 respectively. At 22.8x trailing earnings and roughly 16.5x EV/EBITDA, valuation is not cheap but has compressed from levels that were harder to defend earlier in the year.
The institutional picture adds one notable detail. T. Rowe Price increased its position by 7.7 million shares in the most recent quarter, making it the second-largest holder at nearly 10% of shares outstanding. That is a material addition from an active manager and suggests at least one significant institutional voice has conviction despite the guidance cut. Insiders have been net sellers — CEO Vicente Reynal sold around $13.8 million worth of stock between February and April — though the significance scores on those trades are low, and sales at these levels are consistent with routine executive liquidity activity rather than a directional call.
The July 30 print is ultimately a test of whether Ingersoll Rand can stabilize EBITDA margins and restore confidence in organic growth guidance after a quarter that shook that confidence — and whether the backlog strength bulls cite is converting into revenue at a pace that justifies even the trimmed valuations the Street has assigned it.
See the live data behind this article on ORTEX.
Open IR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
